CAR-T cell therapy expands into leukemia trials and autoimmune research

Medical advancements in CAR-T cell therapy are expanding from oncology into the treatment of autoimmune diseases. This immunotherapy involves genetically modifying a patient's own T-lymphocytes to recognize and attack specific targets, such as cancer cells or defective immune cells.

In Mexico, the Federal Commission for Protection against Sanitary Risks (Cofepris) has authorized the first domestic clinical trial for CAR-T cells. Conducted by the Universidad Autónoma de Nuevo León at the Hospital Universitario Dr. José Eleuterio González, the CARLLA-B1 protocol will evaluate the safety and efficacy of the MB-CART19 therapy in adults with relapsed or refractory acute lymphoblastic leukemia.

Simultaneously, researchers at the Yale School of Medicine are exploring the application of this technology for severe autoimmune conditions, including lupus, multiple sclerosis, and scleroderma. Unlike traditional maintenance treatments, CAR-T therapy is often administered as a single infusion, acting as a ‘living drug’ that can persist and function within the body to target the underlying cause of the disease.